

## CONSENT: MRI CONTRAST

Your Physician has determined that a contrast enhanced Magnetic Resonance Imaging (MRI) study is needed to help diagnose a medical condition. The MRI contrast agent helps to distinguish abnormal tissue from normal.

We want to let you know about rare but potential concerns regarding injection of gadolinium. Nephrogenic Systemic Fibrosis (NSF) is a rare disease causing skin thickening that may prevent bending and extending joints. Patients may also have this condition spread to other parts of the body such as the diaphragm, muscles in the thigh and lower abdomen, and the interior areas of lung vessels. This disease is progressive and may be fatal. The American College of Radiology classifies gadolinium into 3 groups based on their association with NSF. NSF is seen mostly in patients that have advanced renal failure and who have received an injection of Group 1 or Group 3 gadolinium. CPH routinely uses Group 2 gadolinium (ProHance) which has a very low, if any, risk of causing the development of NSF. Gadolinium deposition has recently been found in the brain of people receiving multiple doses over their lifetime regardless of kidney function. Currently there are no known adverse clinical consequences, however the mechanism of gadolinium deposition is not thoroughly understood and research is ongoing.

Risks of gadolinium contrast:

- Allergic reaction: Some people experience temporary itching after receiving MRI contrast. Less than one person in 300,000 will experience a severe allergic reaction which requires treatment.
- Metallic taste in the mouth, tingling in the arm, nausea, or headache in less than 1% (less than 1 in 100) of people.
- Insertion of the needle (small plastic tube) may also cause minor pain, infiltration, bruising and/or infection at the injection site.
- NSF/Gadolinium deposition: As described above

**Please indicate if you have any of the following:**

- Personal history of any kidney disease (e.g. on dialysis, renal transplant, renal surgery, renal cancer or single kidney)
- Diabetes
- Hypertension requiring medication.

Your signature below indicates that you have read and understand this page and the risks described above, including the risk of the rare fibrosing condition NSF and agree to have an MRI and/or MRA with IV gadolinium contrast.

\_\_\_\_\_  
Signature of Patient, Guardian or Legal Representative

\_\_\_\_\_  
Date / Time

\_\_\_\_\_  
Technologist Signature

\_\_\_\_\_  
Date / Time



250 Hospital Place, Soldotna, AK 99669  
Main 907.714.4580, Fax 907.714.4995

RAD012 SP/PMR Rev 12/13/17

Patient Label